Bill Lundberg

Bill Lundberg is President and CEO at Merus, a leading oncology biotechnology company. He was previously Chief Scientific Officer at CRISPR Therapeutics, as well as Vice President and Head of Translational Medicine at Alexion Pharmaceuticals, where he was responsible for R&D from discovery to clinical proof-of-concept. Bill previously held senior positions at Taligen Therapeutics, Antisoma, Xanthus (acquired by Antisoma), Wyeth (now Pfizer) and Genzyme, overseeing the development of diverse portfolios.

Bill received his B.S. in biology from the Massachusetts Institute of Technology (MIT), M.D. from Stanford Medical School and M.B.A. from the University of Massachusetts Amherst. As a post-doctoral fellow, he studied at the Whitehead Institute at MIT. He trained in internal medicine and oncology at Brigham and Women’s Hospital and Dana-Farber Cancer Institute.